Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study

Clinical Therapeutics

Volumn 27, Issue 5, 2005, Pages 578-588

  Ruilope, Luis M ^a   Malacco, Ettore ^b   Khder, Yasser ^c   Kandra, Albert ^c   Bönner, Gerd ^d   Heintz, Daniela ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MEDIAN Kliniken GmbH   (Germany)

Author keywords

Amlodipine; Combination therapy; High risk patients; Hydrochlorothiazide; Valsartan; Vascular markers

Indexed keywords

AMLODIPINE; ANTIGEN; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MARKER; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM LESION; FEMALE; HEALTH CENTER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; POPULATION; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SITTING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; TREATMENT OUTCOME;

EID: 20644459919     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.05.006     Document Type: Article

References (24)

1. [published corrections appear in J Hypertens. 2003;21:2204 and J Hypertens. 2004;22:435] European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
2. Editorial McInnes GT Hypertension control-an old song resung Blood Press 13 2004 69 71
3. for the ALLHAT Collaborative Research Group Cushman WC, Ford CE, and Cutler JA Success and predictors of blood pressure control in diverse North American settings: The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) J Clin Hypertens (Greenwich) 4 2002 393 404
4. for the LIFE Study Group Dahlöf B, Devereux RB, and Kjeldsen SE Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 2002 995 1003
5. for the VALUE Trial Julius S, Kjeldsen SE, and Brunner H VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk Am J Hypertens 16 2003 544 548
6. for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Education Program Coordinating Committee Chobanian AV, Bakris GL, and Black HR The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197] JAMA 289 2003 2560 2572
7. for the VALUE Trial Group Julius S, Kjeldsen SE, and Weber M Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial Lancet 363 2004 2022 2031
8. Weber MA, Julius S, and Kjeldsen SE Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial Lancet 363 2004 2049 2051
9. Waeber B Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension Expert Rev Cardiovasc Ther 1 2003 43 50
10. for the Co-Diovan Study Group Mallion JM, Canetta R, and Trenkwalder P Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy Blood Press Suppl 1 2003 36 43
11. Abstract Lacourciere Y, Hebert D, and Assouline L Effective blood pressure control with valsartan/HCTZ combination therapy in patients with moderate to severe systolic hypertension: The VALOR trial J Hypertens 22 Suppl 2 2004 S301
12. for the Canadian Hypertension Education Program Khan NA, McAlister FA, and Campbell NR The 2004 Canadian recommendations for the management of hypertension: Part II-therapy Can J Cardiol 20 2004 41 54
13. Messerli FH, Oparil S, and Feng Z Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension Am J Cardiol 86 2000 1182 1187
14. for the Val-Syst study Malacco E, Vari N, and Capuano V A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study Clin Ther 25 2003 2765 2780
15. Erhardt LR Endothelial dysfunction and cardiovascular disease: The promise of blocking the renin-angiotensin system Int J Clin Pract 57 2003 211 218
16. Perloff D, Grim C, and Flack J Human blood pressure determination by sphygmomanometry Giradation 88 1993 2460 2470
17. Diggle PJ, Liang KY, and Zeger SL Analysis of Longitudinal Data 1994 Clarendon Press Oxford, UK
18. for the Valsartan/HCTZ Combination Therapy in Brazil Study Group Franco RJ, Goldflus S, McQuitty M, and Oigman W Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population Blood Press Suppl 2 2003 41 47
19. Verdecchia P, and Angeli F Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both Clin Ther 26 2004 460 472
20. Lowe GD, Danesh J, and Lewington S Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis Eur Heart J 25 2004 252 259
21. Booth NA Fibrinolysis and thrombosis Baillieres Best Pract Res Clin Haematol 12 1999 423 433
22. Oubina MP, de Las Heras N, and Vazquez-Perez S Valsartan improves fibrinolytic balance in atherosclerotic rabbits J Hypertens 20 2002 303 310
23. Yasunari K, Maeda K, and Watanabe T Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy J Am Coll Candiol 43 2004 2116 2123
24. Dandona P, Kumar V, and Aljada A Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action J Clin Endocrinol Metab 88 2003 4496 4501